Veliparib: a new therapeutic option in ovarian cancer?

Eleonora Ghisoni, Gaia Giannone, Valentina Tuninetti, Sofia Genta, Giulia Scotto, Massimo Aglietta, Dario Sangiolo, Gloria Mittica, Giorgio Valabrega

Research output: Contribution to journalArticlepeer-review


The role of poly ADP ribose polymerase inhibitors in ovarian cancer is rapidly evolving. Three different poly ADP ribose polymerase inhibitors (olaparib, niraparib and rucaparib) have been already approved as maintenance after response to platinum-based chemotherapy; two of them (olaparib and rucaparib) also as single agents. Veliparib, a novel PARPI, showed promising results in preclinical and early clinical settings. The aim of this review is to discuss veliparib's mechanisms of action, to provide a clinical update on its safety and activity in ovarian cancer, and to highlight future perspectives for its optimal use. Veliparib favorable toxicity profile encourages its use either as monotherapy or in combination. Its peculiar neuroprotective and radio-sensitizing effect warrant further investigation.
Original languageEnglish
Pages (from-to)1975-1987
Number of pages13
JournalFuture Oncology
Publication statusPublished - Jun 1 2019


  • Administration
  • Oral
  • Benzimidazoles
  • pharmacology
  • therapeutic use
  • Clinical Trials
  • Phase II as Topic
  • DNA Breaks
  • Single-Stranded
  • DNA Repair
  • drug effects
  • Female
  • Humans
  • Ovarian Neoplasms
  • drug therapy
  • genetics
  • pathology
  • Poly (ADP-Ribose) Polymerase-1
  • antagonists & inhibitors
  • metabolism
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Poly(ADP-ribose) Polymerases
  • Synthetic Lethal Mutations
  • Treatment Outcome
  • BRCA mutations
  • BRCA-mutated ovarian cancer
  • PARP inhibitors
  • maintenance treatment
  • ovarian cancer
  • poly (ADP-ribose) polymerase inhibitors
  • veliparib


Dive into the research topics of 'Veliparib: a new therapeutic option in ovarian cancer?'. Together they form a unique fingerprint.

Cite this